Glenmark Pharmaceuticals has scheduled a board meeting on November 14, 2025, to consider and approve the unaudited financial results for the second quarter and half-year ended September 30, 2025. The company has also announced a trading window closure for its directors and designated persons from September 30, 2025, to November 16, 2025.
Board Meeting for Financial Results
Glenmark Pharmaceuticals Limited will hold a meeting of its Board of Directors on November 14, 2025, to review and approve the unaudited financial results. This meeting will cover the results for the second quarter (Q2: Jul-Sep) and half-year period that concluded on September 30, 2025.
Trading Window Closure
In compliance with regulations, Glenmark Pharmaceuticals has initiated a trading window closure for its directors and designated employees. This restriction began on September 30, 2025, and will remain in effect until November 16, 2025. The closure ensures that individuals with access to unpublished price-sensitive information cannot trade in the company’s shares during this period, maintaining market integrity during the financial review process.
Source: BSE
